Ivermectin cancer claim

The viral claim points to a preprint, not a published clinical trial, and it does not show ivermectin “matched chemotherapy” in cancer patients. The paper describes 197 people who chose an off-label ivermectin-plus-mebendazole regimen and then self-reported what happened over six months. (zenodo.org) Cancer trials usually test one treatment against another in comparable groups and verify scans, lab results, and side effects through investigators. This report did not randomize patients, did not include a chemotherapy control arm, and relied on patient-reported outcomes rather than independently confirmed tumor assessments. (zenodo.org) The headline number in the preprint was an 84% “clinical benefit ratio” after six months in 197 patients. In the paper, that combined two different categories: 48% who reported “no evidence of disease” or remission and 36% who reported stable disease, meaning no progression during the period measured. (zenodo.org) That is not the same thing as proving a drug shrank tumors better than standard treatment. In many cancers, “stable disease” can reflect a slow-growing tumor, prior treatment effects, or the natural course of illness, which is why oncology studies usually require imaging reviewed under set criteria such as Response Evaluation Criteria in Solid Tumors. (cancer.gov) The report also studied a mixed group rather than one cancer in one setting. Patients had different tumor types, stages, prior treatments, and treatment combinations, which makes broad comparisons to chemotherapy especially hard. (zenodo.org) There is real lab research behind interest in ivermectin as a repurposed cancer drug. Reviews in the scientific literature describe anti-cancer effects in cell studies and animal models, including effects on tumor growth, metastasis, and signaling pathways, but those are early-stage findings and do not establish benefit in patients. (pmc.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov) Human testing is still limited. ClinicalTrials.gov lists a phase two study of ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer, and the National Cancer Institute page for a related pembrolizumab study shows that trial as withdrawn, with no efficacy results posted. (clinicaltrials.gov, cancer.gov) Outside reviewers have raised methodological concerns about the new preprint. Medical oncologist Alfonso Dueñas Gonzalez said the report had high attrition, unverified endpoints, and doses he considered too low to support the conclusions being promoted online. (oncodaily.com) United States regulators have approved ivermectin for specific parasitic infections in humans, not as a cancer treatment. The Food and Drug Administration says ivermectin products are approved at specific doses for certain worms, head lice, and rosacea, and it warns against using unapproved formulations or self-medicating. (fda.gov, fda.gov) The cleanest reading of the evidence is narrower than the viral posts: there is a preliminary, non-randomized, self-reported preprint suggesting a signal worth testing. It does not show ivermectin matched chemotherapy, and it does not settle whether ivermectin helps cancer patients outside controlled trials. (zenodo.org, clinicaltrials.gov, oncodaily.com)